Combination of Continuous Low Doses of Vinorelbine, Cyclophosphamide and Interferon Alpha 2b for Antiangiogenic/Antivascular Effect in Adult Advanced Neoplasm.

Trial Profile

Combination of Continuous Low Doses of Vinorelbine, Cyclophosphamide and Interferon Alpha 2b for Antiangiogenic/Antivascular Effect in Adult Advanced Neoplasm.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jan 2012

At a glance

  • Drugs Cyclophosphamide (Primary) ; Interferon alpha-2b (Primary) ; Vinorelbine (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Acronyms METRO1
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Jan 2012 Status changed from suspended to completed as reported by ClinicalTrials.gov.
    • 27 Jan 2012 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top